H.C. Wainwright Reiterates Its ‘Buy’ Rating on Anavex Life Sciences Corp. (AVXL) with a $42 Price Target

Anavex Life Sciences Corp. (NASDAQ:AVXL) is one of the 10 Best Debt Free Small Cap Stocks to Buy Now.

H.C. Wainwright Reiterates Its ‘Buy’ Rating on Anavex Life Sciences Corp. (AVXL) with a $42 Price Target

vipman/Shutterstock.com

On September 11, 2025, H.C. Wainwright reiterated its ‘Buy’ rating on Anavex Life Sciences Corp. (NASDAQ:AVXL) with a $42 price target. This bullish stance follows new Phase 2b/3 Alzheimer’s data.

Anavex Life Sciences Corp. (NASDAQ:AVXL)’s shares are currently trading well below this target, indicating significant upside potential. Meanwhile, the company announced on September 9, 2025, that its oral therapy blarcamesine noted reduced cognitive decline across key measures in early Alzheimer’s patients. This bolsters confidence in the company’s precision medicine approach.

Anavex Life Sciences Corp. (NASDAQ:AVXL), a biopharmaceutical company, develops novel therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. It is one of the Best Debt Free Stocks.

While we acknowledge the potential of AVXL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AVXL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 12 Best Quantum Computing Stocks to Buy According to Wall Street Analysts.

Disclosure: None.